Leerink Partnrs Reaffirms Outperform Rating for Cartesian Therapeutics (NASDAQ:RNAC)
Related Articles
-
Berenberg Bank Reaffirms “Buy” Rating for Dunelm Group (LON:DNLM)
Dunelm Group (LON:DNLM – Get Free Report)‘s stock had its “buy” rating reaffirmed by Berenberg Bank in a research note issued on Thursday, Marketbeat.com reports. They currently have a GBX 1,410 ($17.55) price target on the stock. Berenberg Bank’s price objective would suggest a potential upside of 44.76% from the company’s previous close. Separately, Jefferies […]
-
The G Goes EV: The New Mercedes G 580 EQ
The Mercedes G-Class has always been a robust climber from Graz, one of the brand’s most successful and lucrative models. The subtle refresh of the new model is one thing; however, by mid-year, the long-awaited electric version will finally be available. Off-road, it’s not just ground clearance and overhangs that determine whether a trail can […]
-
US rate setter tells BBC 'no hurry' to cut interest rates
A key member of the US central bank, Raphael Bostic, tells the BBC rates might only ease "at the end of 2024".